Literature DB >> 16401812

C-reactive protein is a marker for human immunodeficiency virus disease progression.

Bryan Lau1, A Richey Sharrett, Larry A Kingsley, Wendy Post, Frank J Palella, Barbara Visscher, Stephen J Gange.   

Abstract

BACKGROUND: Limited data on acute-phase C-reactive protein (CRP) levels in human immunodeficiency virus (HIV) infection exist.
METHODS: We obtained a single measurement of CRP from 513 HIV-infected men in the Multicenter AIDS Cohort Study to examine the association between CRP and immune suppression and progression to AIDS. We estimated changes in CRP during the course of HIV infection in 81 of these individuals using specimens collected from October 1, 1984, to December 31, 1996.
RESULTS: The cross-sectional associations between log(10) CRP were correlated inversely with CD4 lymphocyte counts (r=-0.17; P<.001) and directly with log10 HIV RNA levels (r=0.20; P<.001). Levels of CRP of more than 2.3 mg/L were associated with a decreased time to the development of AIDS (relative time to AIDS, 0.36; P<.001) compared with individuals with CRP levels of 1.2 mg/L or less, which remained significant after adjustment for CD4 lymphocyte counts and HIV RNA and hemoglobin concentrations. Levels of CRP significantly increased over time with mean slopes of 8.5% (95% confidence interval, 4.9%-12.2%) and 4.5% (95% confidence interval CI, 2.1%-6.9%) per year for individuals with and without progression to AIDS, respectively. Individuals had a geometric mean CRP level of 2.5 mg/L in the 6-month interval before progression to AIDS, which was an increase from a nadir of 1.0 mg/L at 6.5 years before progression to AIDS.
CONCLUSIONS: Levels of CRP were associated with HIV disease progression independent of CD4 lymphocyte counts and HIV RNA levels. In addition, regardless of progression to AIDS, HIV-infected individuals had a significant increase in CRP over time. This may have implications for cardiovascular disease among HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16401812     DOI: 10.1001/archinte.166.1.64

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  81 in total

Review 1.  Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010.

Authors:  James D Neaton; Jacqueline Neuhaus; Sean Emery
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

3.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

4.  MicroRNA biomarkers associated with type 1 myocardial infarction in HIV-positive individuals.

Authors:  Neal Yuan; Rebecca Scherzer; Kahraman Tanriverdi; Jeffrey Martin; Smruti Rahalkar; Priscilla Hsue
Journal:  AIDS       Date:  2019-12-01       Impact factor: 4.177

5.  Systemic inflammation is elevated among both HIV-uninfected and HIV-infected young MSM.

Authors:  Ethan Morgan; Harry E Taylor; Daniel Timothy Ryan; Richard D'Aquila; Brian Mustanski
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

6.  The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease.

Authors:  Jennifer E Ho; Rebecca Scherzer; Frederick M Hecht; Kristinalisa Maka; Van Selby; Jeffrey N Martin; Peter Ganz; Steven G Deeks; Priscilla Y Hsue
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

Review 7.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

Review 8.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

9.  Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

Authors:  Robert C Kaplan; Lawrence A Kingsley; Stephen J Gange; Lorie Benning; Lisa P Jacobson; Jason Lazar; Kathryn Anastos; Phyllis C Tien; A Richey Sharrett; Howard N Hodis
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

10.  Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Authors:  Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.